Revolution Medicines Q2 FY26 net loss widens to $644.4 million; R&D expenses rise to $394.9 million

• Revolution Medicines posted a GAAP net loss of $644.4 million for Q2 2026, widening from a $247.8 million loss a year earlier.
• GAAP R&D expense climbed to $394.9 million from $224.1 million, driven by higher daraxonrasib and zoldonrasib trial and manufacturing costs.
• GAAP G&A expense rose to $110.2 million from $40.6 million on higher stock-based compensation, added headcount, and commercial preparation activities.
• Cash, cash equivalents and marketable securities totaled $3.9 billion at June 30, 2026, reflecting April equity and 0.50% convertible senior notes offerings and a $250 million Royalty Pharma payment.
• Updated 2026 GAAP operating expense guidance to $2.1-$2.2 billion; FDA accepted daraxonrasib NDA for previously treated metastatic pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051602PRIMZONEFULLFEED9804460) on August 05, 2026, and is solely responsible for the information contained therein.